Global Automated Cell Culture Market Extends at a Healthy CAGR of 13.38% by 2032

Introduction

Automated cell culture is a technique that applies enhanced approaches to cultivating and maintaining cell cultures. Maintaining optimal sterility in cell culture traditionally requires several hours of physical, repetitive, and precise labor. In addition, there are many benefits to automating the steps involved in cell culture, such as saving time and money on labor. Automation promotes procedure consistency and delivers sterility that even the most skilled technicians cannot achieve. Automated cell culture systems are user-friendly and can handle high volumes of culture since scale-up is accelerated with automated equipment.

Market Dynamics

The rising Adoption of Liquid Handling Systems Drives the Global Market

Automated liquid handling systems are versatile laboratory machines designed for collecting, combining, and mixing liquid samples. By completing various laboratory procedures, these devices help avoid errors and sample contamination and reduce the amount of manual labor performed by lab professionals. In addition, prominent market participants are creating compact, user-friendly liquid-handling workstations for small and medium-sized laboratories. The increasing demand for early disease diagnosis and treatment of various chronic and life-threatening conditions drives the usage of automated liquid handling systems by diagnostic centers and hospitals. Consequently, the increase in the usage of liquid handling systems in small to large-scale research laboratories for diverse sample handling needs is anticipated to drive the growth of this market throughout the forecast period.

Growing Focus on Regenerative Medicine Creates Tremendous Opportunities

Regenerative medicine is a relatively new medical specialty that strives to give treatments for the replacement of organ/tissue systems in the human body. Cell treatments and regenerative medicine have a tremendous potential to enhance the health-related quality of life of many chronically ill individuals. The impending and growing demand for novel medicines to treat debilitating health disorders compels manufacturers to produce cutting-edge cell culture technologies. The technological advances in automated cell culture increase cell line output and quality. In addition, the rising participation of players in regenerative medicine drives the demand for automated cell culture systems. In turn, the increasing need for novel drugs and the development of robotic cell culture workstations and cell identification devices are providing opportunities in the automated cell culture market.

Regional Analysis

Americas is the most significant shareholder in the global automated cell culture market and is anticipated to grow at a CAGR of 13.31% during the forecast period. The presence of key market participants, a well-developed healthcare infrastructure, substantial per capita healthcare expenditures, increasing financing for research and development, cancer-specific research, and grants from government healthcare agencies are driving the market in this region. In addition, major players, including Thermo Fisher Scientific, Hamilton Company, and Beckman Coulter, Inc., are headquartered in the United States, allowing for early market entry and rapid product delivery. The market for automated cell culture in the United States is anticipated to be driven by the increased prevalence of cancer patients and rising expenditure in R&D to create new treatment options over the forecast period.

Europe is anticipated to experience a CAGR of 12.87% over the forecast period. Due to research and development by manufacturers for the launch of innovative goods, the European market is likely to expand throughout the forecast period. For instance, Tecan launched the Fluent Gx automation workstation for regulated laboratories in 2018. In addition, growing R&D efforts and the biopharmaceutical industry are anticipated to propel the European automated cell culture market. The availability of advanced technology in countries such as Germany and the increasing financing from various public and commercial sources for cutting-edge research contribute to the expansion of the market.

Key Highlights

• The global automated cell culture market size was valued at USD 2.28 billion in 2023. It is expected to reach USD 6.17 billion in 2032, growing at a CAGR of 13.38% over the forecast period (2024-2032).
• By type, the global automated cell culture market is divided into modular automation and whole lab automation. The modular automation segment is the highest contributor to the market and is expected to grow at a CAGR of 13.54% during the forecast period.
• By equipment type, the global automated cell culture market is divided into automated liquid handling systems, microplate readers, robotic systems, automated storage and retrieval systems, and others. The automated liquid handling segment owns the highest market share and is estimated to grow at a CAGR of 13.23% over the forecast period.
• By application, the global automated cell culture market is divided into biopharmaceutical production, diagnostics, gene therapy, drug screening and development, toxicity testing, stem cell research, tissue engineering and regenerative medicine, and others. The biopharmaceutical production segment is the highest contributor to the market and is expected to grow at a CAGR of 13.54% during the forecast period.
• By end-user, the global automated cell culture market is divided into pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, research institutes, and cell banks. The pharmaceutical and biotechnology companies segment owns the highest market share and is anticipated to grow at a CAGR of 14.12% over the forecast period.
• Americas is the most significant shareholder in the global automated cell culture market and is anticipated to grow at a CAGR of 13.31% during the forecast period.

Competitive Players

1. Danaher Corporation
2. Mimetas
3. DefiniGen
4. PreComb
5. Axol Biosciences
6. New Cells
7. Crown Biosciences
8. Ncardia Cell
9. Microsystems Corning Incorporated

Recent Developments

Recent Developments

• January 2024 - Thermo Fisher Scientific announced the release of the GibcoTM Cell Therapy Systems (CTSTM) CellmationTM Software, a first-of-its-kind automation solution made to connect and integrate workflows across multiple Thermo Fisher Scientific cell therapy instruments while enabling cGMP compliance to optimize clinical manufacturing processes for innovators developing breakthrough cell therapies.
• May 2024 - ProPharma declared that it has created an enclosed, fully automated cell manufacturing equipment called the Cell manufacturing Box (CF Box) in collaboration with PBL. Decentralized manufacture of all varieties of Cell & Gene Therapies (CAGT) in Class D (ISO8) or c.n.c. neighboring areas is made possible by this novel, new gadget.

Segmentation

1. By Product
   1. Systems
   2. Consumables
2. By Type
   1. Modular Automation
   2. Whole Lab Automation
3. By Equipment Type
   1. Automated Liquid Handling Systems
   2. Microplate Readers
   3. Robotic Systems
   4. Automated Storage and Retrieval Systems
   5. Others
4. By Application
   1. Organoid Cultivation
   2. Biopharmaceutical Production
   3. Diagnostics
   4. Gene Therapy
   5. Drug Development & Tetsing
   6. Toxicity Testing
   7. Stem Cell Research
   8. Tissue Engineering and Regenerative Medicine
   9. Personalized Medicine
   10. Cell Banking
   11. Bioproduction
   12. Diagnostics & Research
   13. Others
5. By End User
   1. Pharmaceutical and Biotechnology Companies
   2. Hospitals and Diagnostic Laboratories
   3. Research Institutes
   4. Cell Banks